Introduction
Breast cancer is a major global problem, and is one of the most commonly diagnosed cancers among women. In Poland, breast cancer has the highest incidence of all cancers in the female population (22.4%), with 15784 women being diagnosed with breast cancer in 2010, and the second highest mortality rate [1] . Substantial evidence from both epidemiological and experimental studies demonstrates that hormones play a crucial role in the etiology of breast cancer. It has been suggested that androgens influence the risk of breast cancer by directly binding to androgen receptors and affecting breast cell growth and proliferation. They may also influence the development of breast cancer by binding indirectly through their conversion to estradiol, or competitively binding to estrogen receptor-α [2] .
The androgen receptor gene (AR) is located on the X chromosome and is a member of the steroid hormone receptor family of ligand-activated transcription factors. Once bound to androgen, cytosolic AR undergoes a conformational change and enters into the nucleus, where, after dimerization and phosphorylation, it interacts with androgen response elements (AREs) in the promoter region of androgen-dependent genes. This is followed by the recruitment of co-regulatory proteins to ultimately regulate transcriptional activation. AR may also associate with the response elements of estrogen receptors (EREs) in a competitive fashion. The role of androgens and androgen receptor in breast cancer has been not fully elucidated. Androgen receptor is known to be expressed by up to 80% of primary breast cancers, which is similar to, or greater than, the proportion of those expressing estrogen (70%) or progesterone (60%) receptors [3] [4] [5] [6] [7] . Moreover, the AR is the only steroid receptor expressed in the luminal androgen receptor (LAR) subtype of triple-negative breast cancer [8] [9] [10] .
The first exon of the AR gene contains highly polymorphic trinucleotide CAG repeats, which encode a polyglutamine (polyGln) tract of between 10 to 40 glutamine residues in the N-terminal transactivation domain of the AR protein. It has been elucidated that polyGln length inversely correlates with AR transcriptional competence [11] . Results concerning polymorphisms of CAG repeats in the AR gene are controversial due to different study designs and races/ ethnicities of the study subjects, as it is possible that the nature of the population could exert an influence. Therefore, the aim of the study was to determine whether the presence of a CAG repeat polymorphism in the androgen receptor gene is associated with sporadic breast cancer in women. 
Experimental Procedures

Materials
DNA isolation
DNA was extracted from paraffin-embedded tissues for infiltrating ductal breast carcinoma patients using phenol-chloroform extraction and from peripheral blood for healthy women using AxyPrep™ Blood Genomic DNA Kit (Axygen). The paraffin-embedded tissue was treated with xylene to remove the paraffin.
PCR Assay for CAG Repeats Analysis
The CAG repeats in the AR gene were amplified using a pair of primers: the sense ) and 5 pmol of both forward and reverse primers. Amplification was carried out in a GeneAmp2400 thermal cycler (Perkin Elmer). The thermal cycling conditions for the CAG repeats in AR gene were as follows: an initial denaturation step at 94°C for 2 min, followed by 30 cycles at 94°C for 15 s and 20 s at an annealing temperature of 53°C, and 65°C for 2 min. The final extension was performed at 72°C for 10 min.
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GeneScan analyses and Genotyping
The fluorescent PCR products were analyzed by mixing 3 μl of PCR products with 4 μl solution containing: 10 volumes deionized formamide, 2 volumes size standard GS-TAMRA350 and one volume running buffer (50 mg mL -1 Blue Dextran, 20 mM L -1 EDTA). After denaturation (94°C for 5 minutes), the samples were electrophoresed in a 5% Long Ranger (FMC) gel using an ABI PRISM 377™ DNA Sequencer (Applied Biosystems). Digital images of fluorescent gel data were acquired using Data Collection software and analyzed using the GeneScan software program (Applied Biosystems).
To confirm the presence of the CAG repeat allele, PCR products obtained using non-fluorescent primers 
Statistical analysis
The chi-square test was used to confirm whether genotype distribution agreed with the Hardy-Weinberg equilibrium. The chi-square test was also used to assess the significance of differences between the distribution of genotypes/alleles in breast cancer patients and controls. Unconditional multiple logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the relationships between the presence of genotypes/ alleles and the risk of breast cancer, and between the presence of genotypes/alleles and those of clinicalpathological parameters.
Results
This study analyzes the variation in the length of AR gene CAG repeats and their association with breast cancer. The CAG repeat motif in the first exon of the AR gene was amplified from 75 samples taken from patients with infiltrating ductal breast cancer and from 50 controls not diagnosed with cancer. Example results of the DNA sequencing of CAG repeats within the AR gene for breast cancer and control samples used to verify the PCR products are shown in Figure 1 .
The number of CAG repeats in the AR gene ranged from 11 to 30 in the breast cancer group and from 13 to 33 in the control group. In both groups, the most frequently occurring allele contained 22 CAG repeats, being found in 13% of cancer patients and 10.5% of controls. Alleles containing 11 and 12 CAG repeats were identified in women with breast cancer but were absent in control group. However, alleles containing 31 and 33 CAG repeats were found to be present in control group but not in patients with breast cancer. An allele containing 32 CAG repeats was not observed to be present in any group. The number of CAG repeats in the AR gene and their frequency of occurrence in breast cancer samples and controls are given in Figure 2 .
The median number of CAG repeats for breast cancer was 21.5. Alleles containing less than 22 CAG repeats (< 22) were classified as short (S), and those equal to or more than 22 CAG repeats (≥ 22) as long (L). The frequency of genotypes observed in the group of women with breast cancer and controls is not consistent with the Hardy-Weinberg equilibrium. The genotype and allele distribution of CAG repeats in the AR gene Table 2) .
Analyzing the relationship between CAG repeat genotypes and alleles in the AR gene, and the incidence of breast cancer, it was found that the presence of genotype L/L reduces the risk of cancer (OR, 0.37; 95% CI, 0.17 -0.80). The presence of shorter (< 22) alleles appeared to increases the risk of breast cancer (OR, 2.19; 95% CI, 1.31 -3.67), whereas the presence of longer (≥ 22) alleles decreases the risk of breast cancer (OR, 0.46; 95% CI, 0.27 -0.77) ( Table 3) .
The correlation between the presence of CAG repeat genotypes and alleles in the AR gene and the clinical-pathological characteristics of breast cancer are presented in Table 4 . In patients with breast cancer, a statistically significant association between genotype S/S of CAG repeats in the AR gene and high III tumor stage (OR, 2.62; 95% CI, 1.01 -6.77) was observed. No differences were identified with regard to CAG repeat length between lymph node positive versus negative tumors, and the status of estrogen or progesterone receptors.
Discussion
Breast cancer is a hormone-dependent malignancy and cumulative exposure to sex hormones has been proposed to be linked to the development of breast cancer. The polyglutamine tract in the androgen receptor, encoded by CAG repeats in the androgen receptor gene, has been reported to be associated with susceptibility to a number of human diseases, such as prostate cancer, male infertility, polycystic ovary syndrome, cryptorchidism, hirsutism, spinal and bulbar muscular atrophy [12] [13] [14] . However, in the case of sporadic breast cancer, the results are varied and ambiguous. One possible explanation for the discrepancy between results obtained by authors is that different study designs were applied (casecontrol study vs case-only study), and that various populations such as Caucasian or Asian, and different sample sizes or dichotomous repeat length cut-offs were used.
Many authors [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] have found no relationship between the number of CAG repeats in the androgen Table 4 . Association of CAG repeat genotypes and alleles in the AR gene with the clinical-pathological parameters of breast cancer. receptor gene and the risk of breast cancer. Others however, have shown an association between the presence of short [27] [28] [29] or long [30] [31] [32] [33] [34] [35] [36] [37] alleles containing CAG repeats in the AR gene and an increased incidence of breast cancer. For example, Yu et al. [38] indicated that longer CAG repeats in the AR gene are associated with lower grade of tumors, fewer lymph node metastases and longer survival. Suter et al. [36] found that women with a cumulative CAG repeat size of 43 or more had a modest increase in risk for breast cancer (OR=1.3; 95% CI, 1.0 -1.7). In turn Wu et al. [33] demonstrated that women with long CAG repeat alleles (>22 repeats) do not have a significantly increased risk of breast cancer (OR=1.52; 95% CI, 0.80 -2.90).
S -short allele (CAG < 22); L -long allele (≥ 22)
The results of our research on women with sporadic breast cancer have shown: (a) a statistically significant difference between breast cancer and control samples with regard to the distribution of CAG repeats in the AR gene; (b) an association between short (<22) CAG alleles of the androgen receptor gene and an increased risk of breast cancer; (c) an association between long (≥22) CAG alleles of the androgen receptor gene and a decreased risk of breast cancer; (d) a statistically significant relationship between the presence of genotype S/S of CAG repeats in the AR gene and high tumor stage.
The present results suggest that the length of CAG repeats in the androgen receptor gene may have a diverse impact on the occurrence of breast cancer. In addition, the involvement of the CAG polymorphism of the AR gene in the risk of breast cancer may also be affected by other factors, including hormone treatment, polymorphism at other loci and family history [23, 36, [39] [40] [41] .
